What Causes Endometrial Hyperplasia? Hormones, Risk, and Reality

A single hormonal imbalance drives most cases: the uterine lining thickens excessively when estrogen acts on it without enough progesterone to keep the cycle in check. That single disruption explains most cases, from a teenager with irregular periods to a postmenopausal woman on estrogen-only therapy. Identifying which mechanism is driving your overgrowth determines whether the condition can be reversed, simply monitored, or carries a real cancer risk that needs urgent attention.

Below is a clear walkthrough of the hormonal root, the conditions that amplify it, the medications that trigger it, and how the diagnosis is confirmed and managed.

The Hormonal Core of Endometrial Hyperplasia

The endometrium is the inner lining of the uterus, and it responds directly to the two main female sex hormones. Estrogen builds the lining during the first half of the menstrual cycle, while progesterone stabilizes and then sheds it after ovulation. When this seesaw stays balanced, the lining thickens, then sheds predictably each month.

How Unopposed Estrogen Drives Overgrowth

When estrogen continues to stimulate the endometrium without progesterone pushing back, the lining keeps building. Each cycle adds tissue that should have been shed, and over months the endometrium becomes thicker and architecturally irregular. Clinicians call this state unopposed estrogen, and it is the underlying engine behind nearly every case of endometrial proliferation.

Anovulation Removes the Protective Reset

Anovulation, the absence of ovulation, is the most common reason estrogen goes unopposed. Without ovulation, the ovary never releases an egg and never produces the progesterone surge that normally follows. The endometrium then receives estrogen’s “build” signal for weeks without ever hearing the “stop and shed” signal. Conditions that produce chronic anovulation remain a leading contributor to abnormal uterine lining changes, a point emphasized in NCI gynecologic overviews.

Reproductive and Metabolic Conditions That Disrupt the Balance

The hormonal imbalance behind the condition rarely appears in isolation. Several reproductive and metabolic disorders create the exact environment an endometrium needs to overgrow, and recognizing which applies to your situation sharpens both risk assessment and prevention.

Polycystic Ovary Syndrome (PCOS)

PCOS is the textbook cause of chronic anovulation in reproductive-age women. Irregular or absent ovulation means months or years of estrogen without progesterone. Over time, this sustained exposure thickens the uterine lining, and it is one reason heavy, prolonged, or skipped periods in PCOS warrant evaluation rather than reassurance.

Obesity and Peripheral Estrogen Production

Adipose tissue is hormonally active. Fat cells contain an enzyme called aromatase that converts androgens (made by the ovaries and adrenal glands) into estrogen. The more adipose tissue present, the more estrogen circulates. Obesity stands as one of the strongest modifiable risk factors for thickened uterine lining and endometrial carcinoma, independent of menstrual history, a finding ACOG committee opinions reinforce.

Nulliparity, Late Menopause, and Diabetes

Each of these conditions extends total lifetime estrogen exposure without the protective resets that pregnancy and regular ovulation provide:

• ▸Nulliparity: Never carrying a pregnancy to term means fewer months of high progesterone and more cumulative estrogen cycles.
• ▸Late menopause: Onset after age 55 prolongs unopposed estrogen production from the ovaries.
• ▸Diabetes mellitus: Insulin resistance often coexists with obesity and elevated estrogen, compounding hormonal load.

Medications and Medical Treatments That Trigger Overgrowth

Sometimes the hormonal imbalance is introduced by something prescribed for another reason entirely. Several widely used medications carry a well-documented ability to overstimulate the endometrium when not properly counterbalanced.

Estrogen-Only Hormone Replacement Therapy

A woman with an intact uterus who takes estrogen without a paired progestin leaves her uterine lining chemically unprotected. Standard practice is to add a progestin or use a combination product, though cases still occur when therapy is initiated outside current guidelines or when residual endometrial tissue remains after a supracervical hysterectomy.

Tamoxifen and Its Paradoxical Effect

Tamoxifen is a selective estrogen receptor modulator (SERM) widely used in breast cancer treatment and risk reduction. In breast tissue it blocks estrogen, which is why it works against hormone-receptor-positive tumors. In the endometrium, though, it acts as an agonist, meaning it activates estrogen receptors and stimulates growth. This is one of the most common medication-induced causes and a classic example of why endometrial monitoring is part of tamoxifen follow-up.

Estrogen-Secreting Ovarian Tumors

Rarely, an ovarian tumor such as a granulosa cell tumor secretes estrogen directly. These tumors can produce extremely high circulating estrogen and cause rapid endometrial thickening, sometimes in younger women whose presentation would otherwise seem unusual. Estrogen-producing ovarian tumors sit among the uncommon but important causes clinicians rule out when other risk factors are absent, a point highlighted in Mayo Clinic gynecologic references.

“Heads up: Any unexpected bleeding while taking tamoxifen or unopposed estrogen warrants prompt evaluation, because medication-driven overgrowth can progress quickly.

From Simple Hyperplasia to Atypical Changes and Cancer Risk

Not all endometrial hyperplasia carries the same danger. Pathologists classify the condition by how the cells look under the microscope, and that classification predicts how likely the lining is to progress to endometrial carcinoma if left untreated.

Simple, Complex, and Atypical: What the Terms Mean

Simple hyperplasia shows glandular crowding but the cells themselves look relatively normal. Complex hyperplasia shows more architectural distortion, with back-to-back glands, but still without markedly abnormal cells. Atypical hyperplasia adds cellular changes, including enlarged nuclei and irregular chromatin, which signal a higher risk of coexistent or future cancer. Atypical hyperplasia is sometimes called endometrial intraepithelial neoplasia (EIN) and is treated as a direct precursor to carcinoma.

Quantified Progression Risk by Subtype

Estimated progression rates to endometrial carcinoma when untreated help you interpret a pathology report:

These numbers are approximate and depend on the specific study and follow-up interval, but they make one point clear: hyperplasia is a continuum, not a single diagnosis. Most simple cases reverse on their own once estrogen is balanced, while atypical cases demand more aggressive follow-up because a meaningful fraction already harbors or will develop carcinoma.

That escalation from benign to precancerous is exactly why symptom patterns and a timely workup become the deciding factor.

Recognizing Symptoms and Navigating Diagnosis

Symptoms drive most women to seek evaluation, but the pattern of bleeding, the imaging findings, and the biopsy result together build the diagnosis. Knowing what to expect at each step prevents surprises.

Abnormal Bleeding Patterns That Matter

Any bleeding that falls outside a predictable menstrual pattern is worth flagging, especially when the lining has had a long time to thicken. In postmenopausal women, even a single episode of bleeding or spotting is considered abnormal until proven otherwise. In premenopausal women, periods that become much heavier, last longer than seven days, occur less than 21 days apart, or happen after months of absence all warrant evaluation.

Transvaginal Ultrasound and Endometrial Biopsy

Transvaginal ultrasound is usually the first test. In postmenopausal women, an endometrial thickness above 4 mm raises concern and typically triggers biopsy. In premenopausal women, the thickness varies with the cycle phase, so the timing matters more than a single number. Endometrial biopsy, an office procedure that samples the lining through a thin catheter, is the definitive test.

When ultrasound is inconclusive, bleeding persists, or the biopsy shows hyperplasia, follow-up may include hysteroscopy to directly visualize and sample focal lesions.

Interpreting the Findings

A report of “thickened endometrial stripe” without biopsy is not a diagnosis; it only describes what ultrasound sees. A biopsy that returns “insufficient sample” usually means the test should be repeated rather than the result ignored. A confirmed hyperplasia diagnosis is where cause-specific workup begins: reviewing menstrual history, weight, medications, and comorbid conditions like PCOS or diabetes to identify the driver.

Reversing the Cause, Lowering the Risk, and Planning Next Steps

Most cases of hyperplasia without atypia are reversible when the underlying hormonal imbalance is addressed. Atypical hyperplasia is more serious, and management often involves closer surveillance or surgical evaluation.

How Progesterone Therapy Counters the Mechanism

Progesterone directly opposes estrogen at the receptor level. Progestin therapy, delivered orally, by injection, or via a progesterone-releasing intrauterine device, stabilizes the endometrium and triggers shedding. Your clinician’s recommendation on formulation and duration depends on whether you want to preserve fertility, your age, and whether atypia is present.

Weight, Cycle Regularity, and Medication Review

Lifestyle and medication changes target the same underlying mechanism:

• ▸Weight reduction: Even a 5–10% loss lowers peripheral estrogen production in adipose tissue, directly addressing obesity-driven overgrowth.
• ▸Cycle regulation: In PCOS, treating anovulation restores monthly progesterone exposure and breaks the chronic estrogen signal.
• ▸Medication review: Switching from unopposed estrogen to combined therapy or alternative treatments removes the iatrogenic trigger.

Surveillance, Repeat Biopsy, and Surgical Evaluation

Follow-up biopsy typically happens three to six months after starting therapy to confirm the lining has reverted. If atypia persists or progression is suspected, surgical evaluation (often hysteroscopy with dilation and curettage, or hysterectomy in women who have completed childbearing) becomes the safer path. Atypical hyperplasia coexisting with carcinoma in the same specimen is more common than older estimates suggested, which is why thorough evaluation matters.

“Pro tip: Ask your clinician exactly which subtype you have and what the plan is for repeat sampling, because management differs sharply between simple and atypical findings.

Bottom Line

Endometrial hyperplasia is a hormone-driven condition, and identifying which driver applies to your situation (unopposed estrogen, anovulation, obesity, a specific medication, or rarely an estrogen-producing tumor) shapes both risk and response. Most cases without atypia reverse once the imbalance is corrected, while atypical changes require closer follow-up because of their higher cancer risk.

FAQ